Is Clarithromycin Ananta affected by food intake?

No, the drug may be used irrespective of meal intake as food does not influence its bioavailability.

What are the primary contraindications for this product?

Contraindications include hypersensitivity to macrolides, concomitant use with drugs like astemizole, cisapride, pimozide, terfenadine, ergot alkaloids, statins (lovastatin/simvastatin), and specific conditions like congenital QT prolongation or electrolyte imbalances.

How should the dosage be adjusted for patients with renal impairment?

For patients with severe renal failure (creatinine clearance <30 ml/min), the dose should be decreased by 50%.

Clarithromycin Ananta

Name: Clarithromycin Ananta
Brand: Ananta Medicare

Clarithromycin Ananta | Ananta Medicare | mytradeloop

نظرة عامة

Clarithromycin Ananta is a macrolide antibacterial agent indicated for the treatment of various bacterial infections, including those of the upper and lower respiratory tracts, skin and soft tissues, and odontogenic infections. It is also utilized for the eradication of H. pylori in patients with duodenal ulcers and for the management of specific mycobacterial infections.

Systemic antimicrobial
H pylori eradication

تواصل مع المُصنّع عرض الكتالوج

أبرز ميزات المنتج

Inhibits bacterial protein synthesis by binding to the 50S ribosomal unit.
Active against Mycobacterium avium complex (MAC) and other mycobacterial species.
Bioavailability is not significantly influenced by food intake.
Available in 250 mg and 500 mg film-coated tablet dosages.
Bactericidal activity against several strains including H. influenzae, S. pneumoniae, and H. pylori.

تفاصيل المنتج

الاستخدام	Prescription only
Active Substance	Clarithromycin
ATC Code	J01F A09
Dosage Form	Film-coated tablets

التصنيف

طريقة الإعطاء
تصنيف ATC
حالة الوصفة الطبية
الشكل الصيدلاني
المادة الفعالة

المزايا التنافسية

Competitive Advantage

High specific activity against a wide spectrum of aerobic and anaerobic gram-positive and gram-negative microorganisms.
Microbiologically active metabolite (14-hydroxyclarithromycin) provides additive or synergistic effects against H. influenzae.
Effective eradication of H. pylori when used in combination therapy for duodenal ulcer treatment.

Clinical Indication

Upper respiratory tract infections (tonsillitis, pharyngitis, paranasal sinusitis)
Lower respiratory tract infections (bronchitis, acute lobar pneumonia, primary atypical pneumonia)
Skin and soft tissue infections (impetigo, folliculitis, erysipeloid, infected wounds)

1 من 4

الإصدارات

المستندات